Roivant Sciences Ltd. ROIV

Company Overview

Roivant Sciences Ltd. is a biotechnology and healthcare company focused on developing and commercializing medicines through a decentralized operating model built around subsidiary companies known as “Vants.” The company operates primarily in the biopharmaceutical industry, with activities spanning drug development, commercialization, digital health technologies, and healthcare-related data sciences. Roivant’s business model combines centralized operational support with independently managed subsidiaries targeting specific therapeutic areas, including immunology, dermatology, neuroscience, oncology, and rare diseases.

The company’s principal revenue drivers have included commercial product sales, licensing arrangements, collaboration agreements, milestone payments, and equity interests in subsidiary entities. A major commercial asset has been VTAMA (tapinarof), developed through Dermavant Sciences, for inflammatory dermatologic conditions including plaque psoriasis. Roivant has also developed capabilities in drug acquisition, clinical development acceleration, and operational infrastructure sharing across its portfolio companies. Founded in 2014 by Vivek Ramaswamy, the company expanded through acquisitions and the creation of multiple “Vants,” evolving from a pharmaceutical asset incubator into a diversified biotechnology platform with commercial-stage operations and strategic technology investments.